Plasma protein therapeutics is a niche sector within the biotechnology and pharmaceutical industries, plasma protein therapies are biologics differentiated by various factors such as Small, fragile patient populations, Reliance on plasma as the essential starting material, Distinct sole source therapies with no generic equivalents and that cannot be substituted and Complex, lengthy manufacturing processes. Plasma protein therapies are principally indicated to treat chronic, genetic rare diseases and require access to physicians with specialized knowledge in the diagnosis and management of these diseases.
Plasma Protein Therapeutic Market Driving Factors
Technological advancements increase in ageing populace, favourable reimbursement policies, and increased standard of living have led to improved life expectancy are propelling the Plasma Protein Therapeutic market. Besides, advancements in recombinant therapeutic drugs are likely to boost the Plasma Protein Therapeutic market. Development of novel products that offer clinical benefits such as improved efficacy and easy sample plasma extraction techniques are likely to boost penetration of plasma proteins in the market. Companies focus on innovation to manufacture plasma-derived products for the treatment of numerous neurological diseases, like neuropathic pain, Myasthenia gravis, and post-polio syndrome etc.
Plasma Protein Therapeutic Market Challenging Factors
However, changing regulatory reimbursement and lack of skilled professionals is likely to hamper the growth of the plasma protein therapeutic market. Nonetheless, governments supporting research and development of novel products due to rapid advancements in biomedical science and technology to address unmet medical needs are driving the market in future.
Plasma Protein Therapeutic Market Segmental Highlights
The report analyses the global Plasma Protein Therapeutic market based on product, application, and geography.
- The various types of plasma protein therapeutics has been bifurcated into Albumin, Immunoglobulin, plasma-derived Factor VIII. Immunoglobulins, also known as antibodies, they are glycoprotein molecules produced by plasma cells–white blood cells. They act as a critical part of immune response system by specifically recognizing and binding to particular antigens, such as bacteria or viruses, and aiding in their destruction. The Immunoglobulin segment is likely hold the major market share owing to approval of biologics across various indications, ease of administration, and treatment cost.
- The Plasma Protein Therapeutic finds application in hemophilia, idiopathic thrombocytopenic purpura and primary immunodeficiencies etc. Idiopathic thrombocytopenic purpura is an immune disorder in which the blood doesn't clot normally. This condition is now more commonly referred to as immune thrombocytopenia (ITP). The age-adjusted prevalence of immune thrombocytopenic purpura (ITP) is estimated to be 9.5 per 100,000 persons in the USA while its annual incidence is estimated to be 2.68 per 100,000 in Northern Europe.
- Plasma Protein Therapeutic market is studied for the key regions including North America, Europe, Asia Pacific, and Rest of the World. North America’s plasma protein therapeutics market is expected to remain the most attractive, growing at a robust CAGR through the forecast period. Factors such as Availability of high disposable income with the population of this region along with the presences of large patient base suffering from various chronic disorders contributed towards the growth of this region.
- North America is considered as an most important regional market and is projected to experience sensible growth over the forecast period
- In the Asia Pacific region, the market is likely to register a highest growth rate due to consequence of rapidly improving healthcare infrastructure coupled with increasing patient awareness levels regarding the early treatment of the targeted disorders.
Plasma Protein Therapeutic Market Key Players
- Baxter International,
- Biotest
- CSL Behring,
- GRIFOLS, S.A.
- Kedrion
- Octapharma USA, Inc.,
- Shire Plc
- China Biologics
- Plasma Protein Therapeutic Market Key Developments
Plasma Protein Therapeutic Market Key Developments
- June 2016: Shire Plc acquired Baxalta. Shire acquired Baxalta’s product portfolio and a strong pipeline for the treatment of rare diseases
- August 2018: Grifols S.A. acquired 24 plasma donor centers in the U.S. These are operated by Biotest AG
The report analyses the global plasma protein therapeutic market based on product, application, and geography. The various commercially available plasma protein therapeutic products Albumin, Immunoglobulin, plasma-derived factor VIII. Plasma protein therapeutics finds application in Hemophilia, Primary Immunodeficiency Diseases (PID), Idiopathic Thrombocytopenic Purpura (ITP), etc. In terms of region, the plasma protein therapeutics market is studied for the key regions including North America, Europe, Asia Pacific, and Rest of the World. Key competitors of this market include Baxter International, Biotest, CSL Behring, GRIFOLS, S.A., Kedrion Octapharma USA, Inc., Shire Plc and China Biologics among others.
Why to buy this report:
- The report offers changing market dynamics in the plasma protein therapeutic market, presenting historical, current and projected market size in terms of value (USD Million)
- The research study provides an in-depth analysis of the industry value chain focusing on the peer and parent markets of plasma protein therapeutic market
- It presents a comprehensive assessment of geographical regions exhibiting promising growth, potential and niche segments, and a neutral perspective on the plasma protein therapeutic market performance
- The report also offers strategic recommendations in key business segments based on the market estimations and competitive landscape, mapping the key common trends of plasma protein therapeutic market
